#United States #Rochester #FDA Recall #Par Health #Argatroban Injection

Par Health Initiates National Recall of Argatroban Injection

Par Health has announced a voluntary nationwide recall of 22 lots of its Argatroban Injection (250 mg/2.5 mL, 100 mg/mL). This decision comes after reports of the presence of particulate matter, including cellulose and various types of plastics, detected in specific lots of the medication. The contamination raises significant concerns about potential health risks for patients, prompting an urgent response from the company and health authorities.

Details of the Recall

The affected lots of Argatroban include several batches that were distributed to wholesalers and hospitals from December 30, 2024, to May 5, 2026. Par Health is actively notifying all relevant wholesale and hospital accounts regarding the recall. Facilities that received the affected products are instructed to immediately discontinue using or distributing the contaminated lots. If the product has been distributed further, it's essential to notify any additional locations that may have received it.

The specific lots affected by this recall can be identified by their National Drug Code (NDC) numbers and expiration dates, which are outlined in the company’s announcement. For example, Lot 84193 is set to expire in October 2026, while Lot 92596 has an expiration in August 2027.

Health Risks Associated with Contaminated Argatroban

The presence of particulate matter in the Argatroban Injection poses considerable health risks to patients. Administration of the contaminated injection could lead to life-threatening conditions, such as:

• - Pulmonary emboli: Blockages forming in the pulmonary blood vessels.
• - Occlusions of blood vessels: This could cause tissue death and potentially result in organ damage.
• - Inflammation of vein walls: This may trigger clot formation, leading to severe complications.

While there have been no reported adverse events linked to this recall as of now, the risks associated with using contaminated medication are significant enough to warrant this proactive measure by Par Health.

About Argatroban Injection

Argatroban is a direct thrombin inhibitor utilized for the prophylaxis and treatment of thrombosis in adult patients suffering from heparin-induced thrombocytopenia (HIT). Additionally, it serves as an anticoagulant for adults undergoing percutaneous coronary interventions who are at risk for HIT. Given the serious nature of HIT and its potential consequences, maintaining the safety and efficacy of medications like Argatroban is crucial.

Guidance for Patients and Healthcare Providers

Par Health encourages anyone involved with the distribution or administration of Argatroban Injection to check their inventories for the affected lots. Should any issues or concerns arise, healthcare providers and patients can contact Inmar, Inc. at 1-855-648-7909 for updates and next steps. For further medical inquiries or to report any adverse reactions, individuals should use the dedicated lines provided by Par Health.

The U.S. Food and Drug Administration (FDA) is aware of this recall and is monitoring the situation closely. In cases where any adverse reactions or quality concerns arise from the use of the contaminated Argatroban, reports can be submitted through the FDA’s MedWatch program.

Conclusion

The voluntary recall of Argatroban Injection underscores the importance of rigorous quality control measures in pharmaceuticals. For consumers and healthcare providers, being aware of potential risks and actionable steps regarding medication recalls is vital for ensuring patient safety. For ongoing developments regarding this recall, stay connected with Par Health’s official communications and regulatory updates.